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Cell wall polymers isolated from group A streptococci,
as well as lipopolysaccharide from Salmonella typhimu-
rium and synthetic muramyl dipeptide, were injected into
the anklejoints ofrats. The inflammatory responses were
assessed by gross and histologic examination, and edema
was measured by accumulation of radiolabeled albumin
in the limbs. The isolated group-specific polysaccharide
induced extensive edema ofthe articular and periarticu-
lar tissue immediately after injection, and this resolved
in 24 hours. The peptidoglycan moiety did not produce
early edema, but induced an acute exudative reaction fol-
lowed by a proliferative synovitis which resolved after
5 days. Reactions induced by covalently bound complexes
of peptidoglycan and the group-specific polysaccharide
(PG-APS) varied, depending on the size ofthe complex.
Small fragments, derived from mutanolysin digestion,
caused both an acute edematous reaction and transient
RATS given a single systemic injection of an aqueous
suspension of purified peptidoglycan-polysaccharide
(PG-APS) fragments isolated from group A streptococ-
cal cell walls develop a chronic, erosive synovitis.14 Joint
inflammation begins as an acute exudative reaction
which subsides and is followed by a prolonged inflam-
matory process. The chronic phase of disease is charac-
terized by repeated cycles of recurrence and remission
of inflammation.I
This characteristic pattern of acute and chronic dis-
ease is determined in part by the physical properties of
the arthropathic PG-APS preparations injected. Soni-
cated PG-APS preparations consist of a heterogeneous
mixture of fragments which differ in particle size. These
fractions can be separated by differential centrifugation
and have been shown to differ in the relative severity
of acute and chronic inflammation which they induce
after a systemic injection.56 Fractions with higher
molecular weights induce relatively severe chronic
inflammation but little acute inflammation. In contrast,
fractions containing smaller fragments induce more se-
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arthritis. Larger fragments did not cause the immediate
edematous reaction, but induced an acute arthritis that
appeared within 24 hours and evolved into a chronic pro-
cess. Episodes of recurrent inflammation, a distinctive
feature ofjoint inflammation induced by systemic injec-
tion of PG-APS polymers, were not observed following
intraarticular injection of any of the cell wall polymers.
The relative susceptibility of different rat strains to ar-
thritis induced by intraarticular injection paralleled the
responses to systemic injection ofPG-APS. These results
demonstrate that variations in arthropathogenicity are
due, in part, to inherent differences in the phlogistic ac-
tivities ofdifferent cell wall polymers, and that the genetic
control of susceptibility involves regulation ofthe inflam-
matory responses rather than the quantity of cell wall
distributed to the joint. (Am J Pathol 1986, 122:323-334)
vere acute inflammation but less severe chronic disease.
Studies by Chetty et a17 have indicated that low-
molecular-weight, mutanolysin-derived fragments of
PG-APS, or the isolated polysaccharide, induce a tran-
sient acute edematous reaction after systemic injection,
but do not cause more prolonged inflammation. Sys-
temic injection of heat-killed whole cells induces an ero-
sive synovitis after a delay of 39-120 days.
Collectively, these studies suggest that arthropathic
activity of PG-APS fragments varies with particle size.
However, quantitative measurements of PG-APS in
joint tissue after systemic injection indicate that these
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differences are due, at least in part, to differential local-
ization of large and small particles in the joint.6 In the
studies presented here, streptococcal cell wall polymers
were injected directly into the ankle joints of rats to
determine their inflammatory activity independent of
variables such as systemic processing of PG-APS, trans-
port to, and localization in joint tissue. The resulting
reactions were characterized by gross and histologic ex-




Cell wall was prepared as previously described.5
Briefly, Group A, Type 3, Strain D-58 streptococci were
grown in Todd-Hewitt broth (BBL Microbiology Sys-
tems, Cockeysville, Md). The cells were harvested by
centrifugation, washed with phosphate-buffered saline
(PBS), and then disrupted in a Braun MSK Cell
Homogenizer (Bronwill Scientific Inc., Rochester, NY).
The cell walls were collected by centrifugation and then
treated with ribonuclease, trypsin and papain, and ex-
tracted with chloroform-methanol. The purified cell
walls were then washed with PBS, dialyzed against dis-
tilled water, and lyophilized. All preparations were as-
sayed for neutral sugars and amino sugars by gas chro-
matography and for amino acids by high pressure liquid
chromatography. To prepare PG-APS fragments for in-
jection, we suspended lyophilized cell walls in PBS at
a concentration of 20 mg/ml and sonicated them for
70 minutes in a Branson Model 350 sonifier (Branson
Sonic Power Co., Danbury, Conn). After sonication,
the suspension was centrifuged at 10,000g for 30
minutes. The supernatant was removed, checked for
sterility, and stored at 4 C until injected. "PG-APS"
refers to this sonicated preparation of cell wall.
Fractions of PG-APS with average molecular weights
greater than 5 x 106 were prepared by differential cen-
trifugation of sonicated PG-APS.5 The fraction
sedimented by centrifugation of PG-APS at 10,000g for
30 minutes is referred to as the 10P30 fraction and has
an average molecular weight of 500 x 106. The super-
natant of the 10,000g centrifugation is centrifuged at
100,000g for 60 minutes. The pellet, referred to as the
100P60 fraction, has an average molecular weight of
50 x 106. The supernatant of the 100,000g centrifuga-
tion is referred to as the 100S60 fraction, and it has an
average molecular weight of 5.3 x 106. These values
were obtained by light-scattering, which is determined
by the largest particles present. Analysis by gel sieving
indicates that the 100S60 preparations are very hetero-
geneous and include polymers of PG-APS with molecu-
lar weights as low as 30,000.7
Fractions of PG-APS with an average molecular
weight of 5 x 105 or less were prepared by mutanoly-
sin digestion of purified cell walls and were separated
by gel filtration.'
Preparation of Other Cell Wall Polymers
Purified peptidoglycan was prepared by formamide
extraction of streptococcal Group A variant (Strain
A486) cell walls according to the method of Krause and
McCarty.8 The isolated group-specific polysaccharides
from Group A (Strain D-58) and Group A-variant
(Strain K43) were prepared as described by Chetty et al.9
Lipopolysaccharide from Salmonella typhimurium
wild type was obtained from Difco Laboratories
(Detroit, Mich) and from Ribi Immunochem Research,
Inc. (Hamilton, Mont). The lipopolysaccharides were
suspended in sterile PBS and sonicated briefly prior to
injection. Synthetic N-acetylmuramyl-L-alanyl-D-
isoglutamine (muramyl dipeptide) was a generous gift
of Dr. Ernst Wachsmuth of Ciba-Geigy, Basal, Swit-
zerland. The muramyl dipeptide was dissolved in ster-
ile PBS and neutralized with sodium hydroxide prior
to injection. A 1007 solution of muramyl dipeptide gave
a negative limulus test.
Experimental Animals and Injection of
Cell Wall Preparations
Six to nine week old outbred Sprague-Dawley female
rats weighing 150-250 g each were purchased from
Zivic-Miller Laboratories, Allison Park, Pennsylvania.
Inbred Buffalo rats were obtained from Simmonsen
Labs, Billroy, California, and inbred Lewis rats from
Charles River Labs, Wilmington, Massachusetts. Cell
wall preparations were suspended in PBS, sonicated
briefly to form a homogeneous suspension, and 10 MI
of the suspension was injected into the ankle joint by
inserting a 25-gauge needle through the Achilles ten-
don just above the calcaneal process. Control joints
were injected with 10 MI of PBS. The reactions were
scored grossly on a scale of 0-4 as previously de-
scribed. 10 The quantity of PG-APS and other polymers
was based on the rhamnose content or dry weight as
described for each patient. Rhamnose determinations
were made by the method of Dische and Shettles."
Collection and Preparation of Joint Tissues for
Histologic Examination
Rats were sacrificed by ether overdose, and the hind
limbs were harvested. The skin was removed from the
feet, and the tibia and the metatarsals were cut away
a few millimeters from the ankle joint. The joints were
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Figure 1-The clinical course of inflam-
matory reactions induced by different
doses of PG-APS. The ankle joints of
five groups of Sprague-Dawley rats
were given injections of the following:
4.0 (-4 ), 1.5 (O-O), 0.56
(E- *), 0.21 (E[-H I), or
0.08 (A- A) ;Ag rhamnose per
joint. Mean scores of 6 joints ± stan-
dard error of the mean.
DAY AFTER INTRA- ARTICULAR INJECTION
fixed in 10% formalin, decalcified, sectioned longitu-
dinally, embedded in parrafin, cut into 4-5-micron tis-
sue sections, and stained with hematoxylin and eosin
(H&E).
Each tissue section was examined for the following:
1) the presence of an acute exudative reaction with sepa-
ration of the tissue components by edema, vascular con-
gestion, infiltration of the synovial tissue with inflam-
matory cells and the presence of fibrin and extravasation
of red blood cells; 2) the presence of a proliferative re-
sponse with hyperplasia of the synovial lining cells, in-
creased vascularity, and increased numbers of fibro-
blasts in the synovial stroma; 3) the formation of
pannus and replacement of bone and articular carti-
lage by pannus; and 4) the presence of a chronic inflam-
matory reaction with diffuse and focal collections of
lymphocytes and macrophages, fibrosis of the synovial
stroma, and continued hyperplasia of the synovial lin-
ing cells.
Measurement of Edema-Producing Activity
Cell wall preparations were tested for edema-produc-
ing activity as previously described.9 Bovine serum al-
bumin (BSA) was radiolabeled with 1251 (Amersham
Corp., Clearbrook, Ill) by the solid-phase lactoperoxi-
dase method.'2 The rats were given an intravenous in-
jection of I2'l-BSA (approximately 0.12 ,PCi/rat), and
1 hour later each rat was given an intraarticular injec-
tion of PBS in the left ankle joint and one of a cell
wall preparation in the right ankle joint. All cell wall
preparations were suspended in PBS. Thirty minutes
after intraarticular injection, the rats were exsangui-
nated, and their hind limbs were removed. The quan-
tity of 1251 present in the blood and in the hind limbs
was determined by gamma scintillation counting. The
mean counts per minute in the right and left limbs were











DAY AFTER INTRA-ARTICULAR INJECTION
Figure 2-Comparison of the clinical course of inflammatory reactions in-
duced by fractions of PG-APS of different average molecular weight. The
ankle joints of three groups of rats were given injections of 1.5 lAg rham-
nose per joint of the 1OP30 ( ), 10OP60 (- *), or 1OOS60
(A A) fraction of PG-APS suspended in PBS. The mean scores of
8 joints 1 SEM are shown. Control joints, given PBS alone, did not de-
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Results
Dose-Dependent Inflammatory Reactions Induced by
PG-APS and Fractions of PG-APS of Different
Average Molecular Weight
Intraarticular injection of PG-APS fragments in-
duced inflammation which was grossly indistinguish-
able from that caused by systemic injection, although
the reaction developed more quickly. Redness and swell-
ing were apparent within 20-30 minutes after intraar-
ticular injection and reached maximum severity within
24 hours (Figure 1). Intraarticular injection of 0.08 jig
rhamnose/joint induced inflammation in only 2 of 6
joints, and inflammation was grossly apparent for only
2 days. Inflammation developed in all joints given larger
quantities of PG-APS, and both the severity and the
duration of inflammation were directly related to the
dose. Intraarticular injection of PBS resulted in mild
inflammation in 1/6 of the injected joints, which sub-
sided within 24 hours.
Intraarticular injection of the 10OS60, 10OP60, or
1OP30 fractions of PG-APS also induced dose-depen-
dent inflammatory reactions which varied in clinical
course and severity (Figure 2). Inflammation induced
by injection of the 10OP60 fraction was more severe and
the course more protracted than reactions caused by
the same dose of either the 10OS60 or the 1OP30
fraction.
All preparations induced inflammation which
reached maximum intensity within 24 hours of injec-







prolonged episodes of recurrent inflammation compara-
ble to those seen following systemic injection of PG-
APS were not observed.
Reactions Induced by Intraarticular Injection of
Products of Chemical or Enzymatic Cleavage
of PG-APS
The clinical courses of the reactions induced by in-
traarticular injection of 50 jg (dry weight)/joint of
Group A-variant peptidoglycan, the isolated Group-A-
specific polysaccharide, or mutanolysin-derived frag-
ments of PG-APS, are shown in Figure 3 (for compari-
son, the response to 5 jg dry weight of PG-APS is also
shown). The Group-A-specific polysaccharide induced
a marked edematous reaction which was apparent
within 5-10 minutes of injection, reached maximum in-
tensity by 30 minutes after injection, and then resolved
by 24 hours as previously described.9 Peptidoglycan did
not induce the early edematous response. Inflamma-
tion in joints that received pepetidoglycan developed
later and persisted for 3-5 days. Mutanolysin-derived
fragments of PG-APS, with an average molecular
weight of 5 x 105, induced both the edematous response
of the group-specific polysaccharide and the transient
inflammatory reaction of peptidoglycan. A similar
course of edema and transient joint inflammation was
induced by intraarticular injection of PG-APS frag-
ments of approximately 40,000 molecular weight iso-
lated from sonicated PG-APS preparations (data not
shown).
Figure 3-Differences in the clinical course of
reactions induced by different streptococcal cell
wall polymers. The ankle joints of rats were
given injections of 5 Mag (dry weight) of PG-APS
X(L-) or 50 pg of peptidoglycan
(A A), the group-specific polysaccha-
ride (@- ), or small fragments of PG-
APS derived by mutanolysin digestion
(O--- 0). Mean scores of 6 joints
v+ 1 SEM.
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Figure 4-The clinical course of reactions in-
duced by lipopolysaccharide and muramyl
dipeptide. Groups of 6 rats were given intraar-
ticular injections of 0.1 (0- ) or 1.0
(0 O) Ag/joint of lipopolysaccharide from
S typhimurium or 50 (- U) or 1000
(LI- i) Alg/joint of muramyl dipeptide.
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Reactions Induced by Intraarticular Injection of
Related Compounds
Muramyl dipeptide, a structural subunit of pep-
tidoglycan, was tested for inflammatory activity at doses
of 50, 300, and 1000 ,ug/joint. In joints given 50 ,ug,
a mild transient reaction developed at 6-10 hours and
then completely subsided by 24 hours after injection
(Figure 4). Following intraarticular injection of 1000
,ug of muramyl dipeptide, inflammation was grossly ap-
Table 1 -Edema-Producing Activity of Streptococcal Cell Wall Polymers and Related Compounds*
























10 1469 + 50
50 1494 97
10 1261 109
10 1625 + 130
10 1205 + 71
10 1229 + 92
50 1210 + 24
10 1410 + 93
50 1516 + 75
10 1356 + 82



















































* Groups of 3-10 rats were given injections as described in Materials and Methods. Thirty minutes after intraarticular injection of test material, the
rats were exsanguinated, the hind limbs were removed, and the amount of 1251 present in each limb was determined by gamma scintillation counting.
t Mean counts per minute per limb 1 SEM.
t Ratio of counts per minute in the test limb (right) over the control limb (left).
§ Comparison of counts per minute of 1251 in the right and left hind limbs by the Student t test for independent means.
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Figure 5-Comparison of the clinical course of reactions induced by intraarticular injection in Buffalo(- A), Lewis (-O ), or Sprague-Dawley
(0 O) rats of PG-APS. The hind ankle joints of groups of 5 rats of each strain were given either 2.5 mg rhamnose/joint (A) or 0.5 pg rhamnose/joint
(B). The mean joint scores of the Lewis rats were significantly greater than those of the Buffalo rats at all points (P < 0.002). The scores of the
Sprague-Dawley rats were significantly greater than those of the Buffalo rats (P < 0.02) at all time points except from Day 15 to Day 30 with the 0.5-ipg dose.
parent in only 66% of the treated joints. The reaction
reached maximum severity 24 hours after injection and
then gradually resolved by 3 days.
The lipopolysaccharide of S typhimurium, which
shares many biologic activities with peptidoglycan,'3
caused inflammation similar in its clinical course to that
induced by peptidoglycan. Inflammation developed in
100% of the treated joints, was apparent by 2-4 hours
after injection and, although quite severe initially,
resolved by 6 days after injection (Figure 4).
Edema-Producing Activity of Selected
Cell Wall Polymers
The ability of selected cell wall polymers to induce
edema after intraarticular injection was assessed by
measurement of extravasation of 125I-labeled BSA in
the limbs. Limbs harvested 30 minutes after intraartic-
ular injection of either the group-specific polysaccha-
ride of Group A streptococci or fragments of PG-APS
derived from mutanolysin digestion contained sig-
nificantly greater amounts of radiolabeled BSA than
did contralateral control limbs (Table 1). In contrast,
the group-specific polysaccharide of Group A-variant
streptococci did not cause the accumulation of the ra-
diolabel. Injection of comparable quantities of unfrac-
tionated PG-APS or the 10OP60 fraction of PG-APS
also failed to induce significant edema. Injection of 50
Mg of the 10OS60 fraction resulted in a significant ac-
cumulation of 12I' in the test limbs, which is due to the
presence of small quantities of low-molecular-weight
fragments of PG-APS. The isolated peptidoglycan moi-
ety also induced some accumulation of 125I after injec-
tion of 50 jAg peptidoglycan/joint. Neither the lipopoly-
saccharide of S typhimurium nor muramyl dipeptide
caused significant edema.
Comparison of the Response of Different Rat Strains
to Intraarticular Injection of PG-APS
The development of arthritis following intraarticu-
lar injection of two doses of PG-APS into Buffalo,
Lewis, and Sprague-Dawley rats is shown in Figure 5A
and B. The incidence and severity of the response to
Figure 6-Inflammation induced in rat ankle joints by intraarticular injection of 5 mg of PG-APS or 50 lAg of peptidoglycan. A-Acute exudative reac-
tion in synovial tissue 4 hours after intraarticular injection of PG-APS. (H&E, x 400) B-Pannus formation and cartilage erosion 3 days after intraartic-
ular injection of PG-APS. (H&E, x 400) C-Chronic inflammation of synovial tissue 8 days after intraarticular injection of PG-APS. (H&E,
x 100) D-Acute exudative reaction in synovial tissue and exudate in the joint space 3 hours after intraarticular injection of peptidoglycan. (H&E,
x 400) E-Hyperplasia and cellular infiltration of synovial tissue 3 days after intraarticular injection of peptidoglycan. (H&E, x 400) F-Fibrosis
of the synovial tissue 8 days after the intraarticular injection of peptidoglycan. (H&E, x 100)
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the local injection paralleled the inflammation induced
in these strains by systemic injection."0
Histologic Appearance of Reactions Induced by
Intraarticular Injection of Streptococcal
Cell Wall Polymers
Eighteen Sprague-Dawley rats were given intraartic-
ular injections of PBS in the left ankle joint and 10 Mg
of PG-APS in the right ankle joint. At 30 minutes, 4
hours, and 3, 8, and 26 days after injection, groups of
2 or more rats were sacrificed, and ankle joints were
collected and processed for histologic examination. In
PBS-treated control joints there was minimal evidence
of edema of the synovial stroma 4 hours after injec-
tion and small numbers of red blood cells and poly-
morphonuclear leukocytes were present in the synovial
stroma and joint space. At subsequent sacrifice points,
PBS-treated joints appeared normal except for a few
small foci of hyperplasia of the synovial lining cells.
Sections of joints harvested 30 minutes after PG-APS
injection showed a mild acute exudative reaction in the
synovial tissues. By 4 hours after injection, marked
edema and vascular congestion of the synovial tissues
were present. Deposits of fibrin and cells which were
predominantly polymorphonuclear leukocytes were
present in the joint space, in the stroma of the synovial
membrane (Figure 6A), and in the periarticular tissues.
This severe exudative reaction was also present in sec-
tions collected 3 days after injection, but the composi-
tion of the cellular infiltrate had changed with an in-
crease in mononuclear cells. Large amounts of fibrin
continued to be deposited in the joint space and in the
synovial stroma, and hyperplasia of the synovial lin-
ing cells was present. Early pannus formation was
noted, and marginal erosion of the cartilage appeared
in the ankle joint (Figure 6B). In joints harvested 8 days
after PG-APS injection, the severity of the acute inflam-
matory reaction was diminished, and evidence of
chronic inflammation became more apparent. The
proportion of mononuclear cells in the infiltrate con-
tinued to increase and the majority of cells in the tis-
sues and joint spaces were mononuclear. There was con-
tinued hyperplasia of the synovial lining cells, and
hyperplasia of the fibroblasts was evident in the stroma
of the synovial membrane (Figure 6C). Pannus forma-
tion was noted with marginal erosion of the articular
cartilage of some joints. Twenty-six days after PG-APS
injection, inflammation in some joints had completely
subsided, and the joints appeared normal except for
focal fibrosis of the synovial stroma and the presence
of some residual hyperplasia of the synovial lining cells.
In other joints, a mild inflammatory reaction persisted
with a small number of polymorphonuclear leukocytes
and mononuclear cells present and continued presence
of small amounts of fibrin. The synovial lining in these
joints was hyperplastic, and fibrosis was present in the
stroma of the synovial membrane. Pannus formation
and erosion of the margins of the articular cartilage
was noted in some joints. However, in none of the joints
examined was the cartilage destroyed and replaced with
fibrous connective tissue, as is often observed in rats
given systemic injections of arthropathic doses of
PG-APS. 1,3
Like the gross appearance of reactions induced by
the various streptococcal cell wall polymers, the histo-
logic appearance of the reactions also differed. Groups
of 6 rats were injected in both the right and left ankle
joints with 50 Mg of the isolated peptidoglycan, the iso-
lated group-specific polysaccharide, or low molecular
weight fragments of PG-APS derived from mutanoly-
sin digestion. Two rats were sacrificed at 30 minutes,
4 hours, and 3 days after injection.
The reaction induced by 50 ,ig of Group A-variant
peptidoglycan resembled the reaction induced by PG-
APS. Edema, vascular congestion, and hemorrhage
were present 30 minutes after injection, and by 3 hours
an intense fibrinopurulent reaction, comparable in
severity to that present in PG-APS-treated joints, had
developed (Figure 6D). By 3 days after injection, mac-
rophages were prominent in the infiltrate and the syno-
vial lining was hyperplastic (Figure 6E). Although simi-
lar in most respects to the reaction induced by PG-APS,
the reaction induced by peptidoglycan resolved more
rapidly, and by 8 days after injection there was less cel-
lular infiltration in the synovial stroma (Figure 6F).
The reaction induced by the Group-A-specific poly-
saccharide was different in several ways from that in-
duced by the other materials. Thirty minutes after in-
jection there was extensive separation of the tissue
Figure 7-Inflammation induced in rat ankle joints by intraarticular injection of 50 pg of Group A polysaccharide or 50 m*g of mutanolysin-derived frag-
ments of PG-APS. A-Extensive edema of the synovial tissue without cellular infiltration 30 minutes after the intraarticular injection of Group A poly-
saccharide. The arrow indicates bleblike formation involving synovial lining cells. (H&E, x 100) B-Synovial tissue showing no significant change
4 hours after the intraarticular injection of Group A polysaccharide. (H&E, x 100) C-Extensive edema of the synovial tissue with fibrinous exudate
in the joint space 30 minutes after the intraarticular injection of mutanolysin-derived fragments of PG-APS. (H&E, x 100) D-Higher magnification
of synovial tissue showing extensive edema 30 minutes after injection of mutanolysin-derived fragments of PG-APS. (H&E, x 400) E- Hemorrhage
into the synovial tissue and joint space 4 hours after the intraarticular injection of mutanolysin-derived fragments of PG-APS. (H&E, x 100) F-Acute
exudative and hyperplastic reaction of the synovial tissue 3 days after the intraarticular injection of mutanolysin-derived fragments of PG-APS. (H&E, x 100)
Vol. 122 * No. 2
332 ESSER ET AL
components of the synovial stroma by edema associated
with the extravasation of a moderate number of red
blood cells and the deposit of a small amount of fibrin
(Figure 7A). The joint space contained fibrin and a few
red blood cells. A remarkable feature of the reaction,
also shown in Figure 7A, is the formation of bleblike
structures involving the synovial lining cells. Four hours
after the injection there was much less evidence of
edema (Figure 7B). Three days after injection the acute
reaction had subsided and only a few foci were noted
in the synovial stroma that showed fibrosis and infiltra-
tion by mononuclear cells. A paucity of neutrophils in
the exudate was a feature of the reaction induced by
Group-A-specific polysaccharide.
The reaction induced by 50 ,ug of the mutanolysin
digest of cell walls included features of the reactions
induced by both the peptidoglycan and group-specific
polysaccharide moieties, with an additional feature con-
sisting of extensive extravasation of red blood cells.
Thus, by 30 minutes after injection there was marked
edema in the synovial stroma (Figure 7C and D). The
joint space contained a large amount of fibrin and a
few red blood cells. Four hours after injection the ex-
travasation of red blood cells into the synovial stroma
and joint space was extensive (Figure 7E). This was as-
sociated with edema of the stroma and infiltration of
a moderate number of neutrophils and mononuclear
cells. Three days after injection the acute exudative reac-
tion was still present. This was associated with mini-
mal pannus formation and marginal erosion of the ar-
ticular cartilage (Figure 7F).
Intraarticular injection of muramyl dipeptide in-
duced only a transient acute reaction with some focal
proliferation of the synovial lining cells.
Discussion
This paper describes the phlogistic activities of differ-
ent bacterial cell wall polymers and the influence of
genetic background of the host on the response. Intraar-
ticular injection allows analysis of cell-wall-induced in-
flammation independently of variables such as influx
from sequestered deposits, transportation, and entry
into joint tissue, which are part of the pathogenesis after
systemic introduction of PG-APS. Local injection also
requires much smaller quantities of purified material
and gives less individual variation.
Each of the polymers induced characteristic reactions
distinguishable by gross and microscopic observation
of the joints. Fragments of PG-APS derived by soni-
cation of cell wall induced acute exudative reactions
which gradually resolved over a period of weeks. Pep-
tidoglycan induced a similar but more transient reac-
tion, consistent with the greater susceptibility of pep-
tidoglycan to degradation by tissue enzymes.14 The
group-specific polysaccharide induced extensive edema
over the first 30 minutes, and during the acute reaction
relatively few polymorphonuclear leukocytes were pres-
ent in the infiltrate. This paucity of inflammatory cells
may be related to the inability of the group-specific poly-
saccharide to activate the alternate complement
pathway. 1S
The smaller mutanolysin-derived fragments of PG-
APS induced features of both the acute edematous reac-
tion induced by the group-specific polysaccharide and
the fibrinopurulent reaction induced by the peptidogly-
can moiety and in addition induced hemorrhage into
the synovial tissue. However, the reaction was of shorter
duration than was the reaction induced by PG-APS
fragments derived by sonication. Injection of even 50
Mg of mutanolysin-derived fragments induced only a
very transient exudative reaction. Although of only
limited arthropathic activity themselves, these frag-
ments may increase the arthropathogenicity of other
fragments. Chetty et al9 have proposed that the in-
creased vascular permeability induced in the limbs by
small PG-APS polymers, or by the isolated group-
specific polysaccharide, could promote the localization
of systemically injected arthropathic PG-APS in the
joint.
The early reactions induced by intraarticular injec-
tion of high molecular weight fragments of PG-APS
resembled grossly and histologically the reactions in-
duced by systemic injection of PG-APS and purified
cell wall fragments from other bacteria."4 16,17,17a How-
ever, reactions induced by intraarticular injections do
not progress to joint destruction, and episodes of remis-
sion and recurrence do not occur. This fundamental
difference may be the result of the smaller quantities
of PG-APS injected, and the failure of these small doses
to induce systemic immunity or immune dysfunc-
tion.1819 Alternatively, recurrent inflammation induced
by systemic injection of PG-APS may be due to the con-
tinued release of PG-APS from an extraarticular source
and the deposition of this material in the joints. No
such reservoir is present after intraarticular injection,
and the inflammatory reaction gradually subsides as the
injected PG-APS is degraded or cleared from the tis-
sues. Consistent with this possibility is the observation
that inflammation in joints initially treated with PG-
APS can be reactivated by systemic reinjection of small,
normally subarthropathic doses of PG-APS.20
Several of the known biologic activities of streptococ-
cal cell walls may contribute to the reactions observed.
Both peptidoglycan and PG-APS polymers activate the
alternate complement pathway.15 Complement pathway
intermediates induce lysosomal enzyme release from
polymorphonuclear leukocytes, increase capillary
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permeability, and are chemotactic for leukocytes.2' In
addition, the cell walls of Group A streptococci acti-
vate macrophages,22 causing the release of lysosomal
enzymes,23 and are polyclonal activators of lymphoid
cells.24 These activities could represent significant mech-
anisms of tissue injury in the joint.25
Measurement of edema-producing activity by ex-
travascularization of 125I-labeled BSA further demon-
strates the difference in biologic activities of the vari-
ous cell wall polymers. In agreement with gross and
histologic observation of the joints, intraarticular in-
jection of the Group A-specific polysaccharide or small
mutanolysin-derived fragments of PG-APS results in
much more edema than produced by peptidoglycan or
high-molecular-weight PG-APS polymers.
The edematous reaction induced by the Group-A-
specific polysaccharide and small fragments of PG-APS
is similar to the reaction that develops in rats 4fter sys-
temic injection of dextran.26 Dextran-induced edema
is mediated by histamine and 5-hydroxytryptamine,
which are released from tissue mast cells27 after the in-
teraction of dextran with a mast cell membrane recep-
tor.28 A similar interaction may occur between mast cells
in joint tissue and the group-specific polysaccharide,
because degranulation of mast cells has been observed
in the joint after injection of the group-specific poly-
saccharide.29
The observation that PG-APS polymers which differ
in size also differ in their inflammatory activity after
local injection is consistent with the findings of previ-
ous studies. Fractions of PG-APS of different average
molecular weight induce acute and chronic inflamma-
tion of different severity after systemic injection.5'6 This
is associated with the quantity of the different PG-
APS polymers which localize to the joint.6 Local in-
jection, as described here, suggests that PG-APS poly-
mers of different size also differ in their intrinsic inflam-
matory potential, independent of transport to and
localization in the joint.
We have previously shown that Lewis and
Sprague-Dawley rats are susceptible and Buffalo rats
are relatively resistent to arthritis induced by systemic
injection of PG-APS.10 Susceptibility is controlled by
multiple genes which are not associated with the ma-
jor histocompatibility complex.4 '0 The present report
shows that the relative susceptibility of rat strains to
joint inflammation is the same after local injection.
Therefore, susceptibility or resistance reflects genetic
control of the inflammatory response rather than fac-
tors regulating systemic processing or delivery of PG-
APS into synovial tissue. This is consistent with other
studies which show that similar amounts of PG-APS
localize to the joint tissues of resistant and susceptible
strains of rats following systemic injection.30
Whether polymers of the types used in these studies
are released during in vivo degradation of streptococci
has not been established. The fact that arthritis develops
in rats after a relatively long latent period following in-
jection of heat-killed Group A or Group B streptococ-
cal cells suggests that arthropathic complexes can be
liberated in vivo."'7 Use of the muralytic enzyme
mutanolysin to treat streptococcal cell-wall-induced ar-
thritis results in the resolution of the acute disease and
prevention of chronic joint disease. Although the cell
wall material is not entirely removed from the tissues
as a result of this treatment, it appears to be degraded
to small fragments, which are able to persist but are
no longer arthropathic.31 It is interesting to note that
the immediate edematous response to an intraarticu-
lar injection of APS or mutanolysin-derived PG-APS
fragments reported here is similar to the transient limb
edema which develops when mutanolysin is given im-
mediately after PG-APS.31 Whether toxic polymers of
microbial origin play a role in rheumatoid arthritis and
arthritis associated with enteric disease is discussed in
a recent review.32
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